Related Experiment Video

Updated: Jun 22, 2026

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

Interferon-beta treatment in multiple sclerosis attenuates inflammatory gene expression through inducible activity of

George P Christophi1, Michael Panos, Chad A Hudson

  • 1Department of Neurology, SUNY Upstate Medical University, Syracuse, NY 13210, USA.

Clinical Immunology (Orlando, Fla.)
|June 30, 2009
PubMed

Insights

Interferon-beta treatment for multiple sclerosis (MS) boosts the protein tyrosine phosphatase SHP-1. This upregulation of SHP-1 is key to reducing inflammatory responses and gene expression involved in MS.

Area of Science:

  • Immunology
  • Neuroimmunology
  • Molecular Biology

Background:

  • Multiple Sclerosis (MS) is an autoimmune disease impacting the central nervous system.
  • Interferon-beta is a standard treatment for MS, working through immune modulation.
  • The precise mechanisms of Interferon-beta's therapeutic effects in MS require further elucidation.

Purpose of the Study:

  • To investigate the role of the protein tyrosine phosphatase SHP-1 in the therapeutic action of Interferon-beta in MS patients.
  • To determine if Interferon-beta treatment alters SHP-1 levels and function in peripheral blood mononuclear cells (PBMCs) from MS patients.
  • To analyze the impact of SHP-1 modulation on key inflammatory signaling pathways in MS.

Main Methods:

  • Treatment of MS patients with interferon beta-1a (Rebif) and analysis of SHP-1 levels and function in PBMCs.
  • In vivo and in vitro studies examining the effects of Interferon-beta on SHP-1 expression and activity.
  • Analysis of STAT1, STAT6, and NF-kappaB signaling pathway activation in response to Interferon-beta and SHP-1 modulation.
  • Experimental depletion of SHP-1 in cultured PBMCs to assess its necessity for Interferon-beta's anti-inflammatory effects.

Main Results:

  • Interferon-beta treatment significantly increased SHP-1 levels and function in MS patient PBMCs.
  • In vivo treatment led to decreased NF-kappaB and STAT6 activation, and increased STAT1 activation.
  • In vitro studies confirmed SHP-1 induction by Interferon-beta, correlating with reduced NF-kappaB and STAT6 activation.
  • Depletion of SHP-1 abolished the anti-inflammatory effects of Interferon-beta, confirming its critical role.

Conclusions:

  • Interferon-beta treatment upregulates SHP-1 expression in MS.
  • SHP-1 acts as a crucial mediator of Interferon-beta's anti-inflammatory effects by reducing pro-inflammatory transcription factor activation.
  • Targeting SHP-1 may represent a novel therapeutic strategy for managing MS pathogenesis.

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...